Jasper Therapeutics, Inc.(JSPR)

$0.70—

Chart

Jasper Therapeutics, Inc.(JSPR)

NASDAQ

$0.70—

Chart Studio

JSPR(JSPR)

JSPR

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.08

Nov 9, 2026 · Reports before open

Revenue Estimate

$12M

Analyst Sentiment

Wall St. Consensus

Buy

12 analysts·Moderate coverage

Score

8 Buy (67%)4 Hold (33%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

867%

Hold

433%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$2.00

+183.7%

Consensus

$2.50

+254.7%

Bull

$3.00

+325.6%

12-Month Target Range12 analysts

$2.00$2.50$3.00

Current $0.70Consensus

Current Price

$0.70

Upside to Consensus

$1.80

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-98.55%

EPS—

FY2028

Rev+389.07%

EPS—

FY2029

Rev+176.47%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$12M	$173,800	$850,000	$2M	$34M
Low	$12M	$173,800	$850,000	$2M	$34M
High	$12M	$173,800	$850,000	$2M	$34M
EBITDA Avg	$-12M	$-14M	$-18M	$-22M	$-28M
Low	$-18M	$-26M	$-35M	$-22M	$-28M
High	$-5M	$-1M	$-1M	$-22M	$-28M
EBIT Avg	$-12M	$-15M	$-19M	$-23M	$-28M
Low	$-19M	$-27M	$-36M	$-23M	$-28M
High	$-6M	$-2M	$-2M	$-23M	$-28M
Net Income Avg	$-12M	$-15M	$-19M	$-23M	$-28M
Low	$-19M	$-27M	$-36M	$-23M	$-28M
High	$-6M	$-2M	$-2M	$-23M	$-28M
EPS Avg	$-0.67	$-0.72	$-0.87	$-1.18	$-1.46
Low	$-0.99	$-1.40	$-1.87	$-1.18	$-1.46
High	$-0.31	$-0.11	$-0.09	$-1.18	$-1.46
Analysts (Rev / EPS)	5 / 2	5 / 3	4 / 5	2 / 1	2 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027	Q1 2028	Q2 2028
Revenue Avg	$12M	—	—	—	—	—	—	—
Low	$12M	—	—	—	—	—	—	—
High	$12M	—	—	—	—	—	—	—
EBITDA Avg	$-2M	—	—	—	—	—	—	—
Low	$-6M	—	—	—	—	—	—	—
High	$3M	—	—	—	—	—	—	—
EBIT Avg	$-2M	—	—	—	—	—	—	—
Low	$-6M	—	—	—	—	—	—	—
High	$3M	—	—	—	—	—	—	—
Net Income Avg	$-2M	$-13M	$-860,908	$-860,908	$-1M	$-1M	$-13M	$-13M
Low	$-6M	$-14M	$-860,908	$-860,908	$-1M	$-1M	$-13M	$-13M
High	$2M	$-12M	$-860,908	$-860,908	$-1M	$-1M	$-13M	$-13M
EPS Avg	$-0.08	$-0.44	$-0.03	$-0.03	$-0.04	$-0.04	$-0.45	$-0.46
Low	$-0.20	$-0.48	$-0.03	$-0.03	$-0.04	$-0.04	$-0.45	$-0.46
High	$0.08	$-0.40	$-0.03	$-0.03	$-0.04	$-0.04	$-0.45	$-0.46
Analysts (Rev / EPS)	5 / 2	— / 2	— / 1	— / 1	— / 1	— / 1	— / 1	— / 1

Earnings Surprises

Recent Analyst Actions

Aug 12, 2026Piper Sandler

Piper Sandler Starts Jasper Therapeutics (JSPR) at Overweight

Target:$2.00

+123.9%from $0.89

May 15, 2026RBC Capital

Jasper Therapeutics price target lowered to $3 from $4 at RBC Capital

Target:$3.00

+257.3%from $0.84

Jan 9, 2025RBC Capital

Jasper Therapeutics price target lowered to $48 from $68 at RBC Capital

Target:$48.00

+171.0%from $17.71

Dec 5, 2024BMO Capital

BMO Capital Starts Jasper Therapeutics (JSPR) at Outperform

Target:$63.00

+192.6%from $21.53

May 6, 2024H.C. Wainwright

H.C. Wainwright Starts Jasper Therapeutics (JSPR) at Buy, "an underappreciated gem in the autoimmune and inflammatory disease space"

Target:$65.00

+165.1%from $24.52

Apr 3, 2024Evercore ISI

Evercore ISI Starts Jasper Therapeutics (JSPR) at Outperform

Target:$65.00

+148.1%from $26.20

Feb 7, 2023Cantor Fitzgerald

Cantor Fitzgerald Reiterates Overweight on Jasper Therapeutics, Lowers Price Target to $6

Target:$6.00

+212.5%from $1.92

Jan 11, 2023Credit Suisse

Credit Suisse Maintains Outperform on Jasper Therapeutics, Lowers Price Target to $3

Target:$3.00

+81.8%from $1.65

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance